Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas | Norris Cotton Cancer Center
Skip to main content
x
Norris Cotton Cancer Center
In This Section
 
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Principal Investigator (?)
Study Number
A071601
Summary
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.

0